



NEXT GENERATION THERAPEUTICS THROUGH NOVEL DRUG DELIVERY SYSTEMS: ADVANCES, CHALLENGES, AND TRANSLATIONAL PERSPECTIVES

AMIT SAMANTA, DIBYENDU SHIL*, BISHAL SARKAR, DEVANJAN CHAKRAVERTY, SHIRAJUL
MONDAL, MD. MASUD REZA, SANGLAP MALLIK

Mata Gujri College of Pharmacy, Kishanganj, Bihar, India

Submitted on: 24.09.2026;

Revised on: 28.09.2026;

Accepted on: 05.10.2026

ABSTRACT

Conventional drug delivery systems are often limited by poor solubility, rapid metabolism, systemic toxicity, and inadequate patient compliance. To overcome these limitations, novel drug delivery systems (NDDS) have emerged as advanced therapeutic platforms capable of improving bioavailability, stability, and site-specific delivery. NDDS integrate nanotechnology, polymer science, and molecular targeting to achieve controlled and targeted release while minimizing adverse effects. Various carriers including liposomes, niosomes, dendrimers, polymeric nanoparticles, nanogels, nano emulsions, microspheres, and lipid polymer hybrids have demonstrated significant potential in the delivery of small molecules, peptides, nucleic acids, and phytochemicals. In addition, stimuli responsive and surface functionalized nanocarriers enable selective release in response to physiological or external triggers such as pH, enzymes, temperature, magnetic field, and light. These systems have shown promising applications in oncology, infectious diseases, neurological disorders, and gene therapy. Despite considerable progress, challenges related to nanotoxicity, large scale manufacturing, regulatory standardization, and environmental safety continue to hinder clinical translation. Current research focuses on integrating artificial intelligence and computational pharmacokinetic modelling to support precision nanomedicine. Overall, NDDS represent a transformative approach in pharmaceutical sciences with the potential to improve therapeutic efficacy, safety, and patient outcomes.

Keywords

Novel drug delivery systems; Nanocarriers; Targeted drug delivery; Nanotechnology

Corresponding author: Dr. Dibyendu Shil

E-mail: dibyendu.mgcop@gmail.com

Indian Research Journal of Pharmacy and Science; 47(2026) 3664-3678

Journal Home Page: <https://www.irjps.in>

1. INTRODUCTION

Conventional drug delivery systems like tablets, capsules, suspensions, and injections have remained the mainstays of pharmaceutical treatment for many years. But though employed extensively, such forms of dosages are usually plagued by several disadvantages such as poor solubility, low bioavailability, extensive metabolism, dose dependent toxicity, and inability to attain site specific drug concentration¹. Such issues tend to cause fluctuations in plasma levels of drug concentrations, requiring repeated dosing and resulting in dose dependent reduced efficacy and patient compliance². Additionally, the traditional approaches tend to subject diseased and healthy tissues to the active drug, leading to unacceptable systemic side effects and therapeutic inefficiency³. The development of modern therapeutics has thus moved toward systems capable of exactly controlling the rate, time, and site of drug delivery. This revolution brought into being the concept of Novel Drug Delivery Systems (NDDS), which are designed to overcome the disadvantage of the traditional dosage form and deliver maximal pharmacokinetic and pharmacodynamic profiles⁴. NDDS utilizes novel materials, nanotechnology, and molecular engineering techniques to deliver drugs in controlled, sustained, and targeted ways in an attempt to deliver their maximum therapeutic performance and reduce toxicity⁵. The main aim of an NDDS is to provide the active drug ingredient to the target site of action with the appropriate concentration and for an optimal amount of time. This is done through approaches like passive and active targeting, controlled release devices, and functionalization of delivery carriers on the surface⁶. During the last two decades, tremendous advances in material science, polymer chemistry, and nanotechnology have transformed the design and formulation of such systems. Nanocarrier based products such as liposomes, niosomes, polymeric nanoparticles, dendrimers, solid lipid nanoparticles, nanogels, and nano emulsions have become multifunctional platforms for drug, gene, and bioactive molecule delivery⁷. Nanotechnology has taken the role of a cornerstone of next-generation therapeutics by providing accurate control over particle size, surface charge, morphology, and release kinetics⁸. The nanoscale regime (classically

1-100 nanometers) maximizes surface area to volume ratio, thus drug dissolution, cellular uptake, and biodistribution are enhanced. Besides, nanocarriers are also capable of defending unstable drugs like peptides, nucleic acids, and phytochemicals against enzymatic hydrolysis, thus enhancing stability and the therapeutic half-life⁹. Surface functionalization of the surfaces of nanocarriers with ligands like antibodies, peptides, or aptamers is capable of delivering active targeting to achieve selective drug concentration in infected tissues like tumors or inflamed organs. One of the most important benefits of NDDS is that it has the ability to deliver controlled and sustained drug release, which may be sustained at near therapeutic plasma concentration for long periods of time without inducing peak and trough¹⁰. Controlled release systems were reported to be highly beneficial in the management of chronic disease, reducing side effects, and enhancing compliance to long term therapy. In addition, NDDS may also be designed to respond to specific physiological or environmental stimuli like pH, temperature, magnetic field, enzymatic activity, or redox potential so that site specific and time dependent drug delivery can be achieved¹¹. Such so called stimuli responsive or smart systems are a significant step toward precision and personalized medicine. The use of NDDS is diversified in various therapeutic classes ranging from oncology, infection therapy, neurologic diseases, cardiovascular disease, and gene therapy¹². In cancer therapy, for instance, nanocarriers such as liposomes and polymeric nanoparticles have found applications to increase delivery of anticancer drugs to the target cancer tissue, thereby reducing systemic toxicity and tumor regression. In neurology, the synthesis of blood brain barrier-crossing nanocarriers has provided new perspectives to control diseases like Alzheimer disease, Parkinson disease, and glioblastoma. Analogously, NDDS has also played a critical role in enhancing the solubility and bioavailability of poorly available phytocompounds like curcumin, silymarin, and quercetin and thereby proving the versatility of nanotechnology in phytopharmaceuticals¹³. Despite dramatic progress, there are a couple of challenges that currently restrict universal clinical application of NDDS. Scale-up related problems, reproducibility, stability, regulatory uncertainty, and nanotoxicity are major challenges.




Fig 1: Revolutionizing Drug Delivery with NDDS

The physicochemical nature of nanocarrier complexity is inclined to be surmised by off-target biological interactions such as immunogenicity, targeting within non target organs, and challenges of large-scale manufacturing. Regulatory bodies like the United States Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have therefore placed emphasis on the use of standardized characterization standards, long-term toxicity, and good quality controls prior to market approval ¹⁴. One of the other important aspects of NDDS studies is employing computational and in silico strategies for the prediction of pharmacokinetic profiles, optimization of formulation parameters, and reduction of experimental loads. Physiologically based pharmacokinetic (PBPK) modeling, quantitative in vitro and in vivo extrapolation (QIVIVE), and artificial intelligence empowered formulation design are starting to be the potent tools that speed up development and lower attrition rates in drug discovery ¹⁵. The synergy of nanotechnology and data driven modeling is a new horizon of personalized drug delivery and precision medicine.

The present review is an overview of novel drug delivery systems, with focus on their design principles, mechanism-based understanding, and recent advances. It also identifies the translational barriers to their therapeutic use and strategies under development for their surmounting. By considering scientific and regulatory benefit, this article aims to present an integrated overview of how NDDS are revolutionizing the face of the pharmaceutical sector

and paving the way to safer, more efficacious, and patient-centered therapeutic modalities.

2. CLASSIFICATION OF NOVEL DRUG DELIVERY SYSTEMS

Novel Drug Delivery Systems (NDDS) is a broad term for sophisticated drug formulations that alter the pharmacokinetic and pharmacodynamic drug effect. They facilitate enhanced bioavailability, extended circulation time, targeted distribution, and sustained release. NDDS may be categorized broadly into three large groups: lipid-based systems, polymer-based systems, and complex or hybrid systems ¹⁶.

2.1. Lipid Based Systems

Lipid based carriers are among the oldest and best researched NDDS. They are biocompatible and can encapsulate hydrophilic and lipophilic drugs. Lipid based carriers constitute elastic vesicular or particulate systems that mimic natural membranes and possess the capability to deliver improved cellular uptake ¹⁷.

Liposomes are phospholipid bilayer vesicles that self-assemble into spherical structures with an aqueous core interior. They have the ability to entrap a broad range of drugs and shield them against enzyme breakdown. The liposome products Doxil and Ambisome have been extremely successful in a clinical setting as anticancer and antifungal infection medications ¹⁸.

Niosomes are ionic surfactant vesicles of similar structure to liposomes but with better chemical

Nanoemulsions are oil-water dispersion stabilized with surfactant that is thermodynamically stable. They have high surface area, increased hydrophobic solubilization of drugs, and improved bioavailability.

Microemulsions are spontaneous mixtures of surfactant, water, and oil that are amenable for use as drug delivery vehicles of parenteral, topical, and oral drugs.

Microspheres are polymer or biodegradable spherical carriers such as chitosan or polylactic acid. Microspheres are used to release the drugs in weeks

or months, which is usually applied in hormone replacement therapy and immunization.

Hybrid polymer-lipid nanoparticles combine the stability of polymers and biocompatibility of lipids to provide controlled release and effective encapsulation of nucleic acids and small molecules.

Nanosponge systems are porous, polymeric networks that can entrap hydrophobic molecules and release them over time and thus be useful for sustained drug delivery products in oral and topical formulations.

Table 1. Major Types of Novel Drug Delivery Systems

Types	Examples	Composition
Lipid based systems	Liposomes, Niosomes, SLN, Transfersomes, Ethosomes	Phospholipids, surfactants, cholesterol
Polymer based systems	Polymeric nanoparticles, Dendrimers, Nanogels, Micelles	Synthetic or natural polymers such as PLA, PCL, PEG, chitosan
Hybrid and complex systems	Nanoemulsions, Microemulsions, Microspheres, Polymer lipid hybrids, Nanosponges	Combination of lipids, polymers, and surfactants

NDDS may be classified categorically strictly according to their structural components and physicochemical characteristics. Lipid based systems are utilized for bioavailability and membrane permeability enhancement; polymer-based systems are used for sustained and stimuli responsive delivery; and hybrid systems integrate the two for multi-functional delivery. All of these categories possess inherent design virtues and limitations, and choice is based on therapeutic intent, drug nature, and administration route.

3. DESIGN PRINCIPLES AND MECHANISTIC BASIS OF NOVEL DRUG DELIVERY SYSTEMS

Design and functionality of future drug delivery systems are based on the delivery of therapeutic drugs at the required rate, duration, and site of action. They apply material science principles, molecular targeting, and biologic interaction to exert total control over pharmacokinetics and pharmacodynamics. There must be a clear insight

into mechanisms of action so that efficacy is maximized and toxicity is minimized ²⁶.

3.1. Principles of Controlled and Targeted Drug Release

Controlled release of drugs is designed to achieve drug concentration within the therapeutic range for an extended period of time. Drug release mechanisms from nanocarriers are generally diffusion, degradation, swelling, and erosion of matrix material ²⁷. Rate of release is regulated by adjusting the physicochemical characteristics of the carrier, e.g., polymer composition, crystallinity, particle size, and surface charge. Targeted drug delivery is the selective administration of the drug molecule to the target tissue or cells with a gain in efficacy and decrease in systemic side effects. Targeting may be through passive mechanisms, for example, the enhanced permeability and retention (EPR) effect, or active mechanisms by molecular recognition by surface ligands ²⁸.




Fig 3: Design Principles and Mechanistic Basis of NDDS

3.2. Passive and Active Targeting Strategies

Passive targeting takes advantage of the physiological characteristics of affected tissue. Tumors, for example, have leaky vasculature with limited lymphatic drainage, so nanosized particles can linger in the tumor microenvironment alone. The EPR effect permits improved local drug concentration without the use of an external targeting ligand ²⁹. Active targeting is the surface modification of nanocarriers with target ligands like monoclonal antibodies, peptides, folic acid, aptamers, or carbohydrates that bind to receptors overexpressed on the target cells ³⁰. Active targeting enables receptor mediated endocytosis, which results in greater intracellular drug levels. For instance, folate receptor targeting has been successfully employed for delivering anticancer drugs to ovarian and breast cancer. Transferrin conjugated particles have been reported to allow improved delivery through the blood brain barrier for neurotherapeutic targeting.

3.3. Surface Modification and Functionalization

Surface modification is a critical design factor in the construction of NDDS. Functionalization not only improves stability in body fluids but also controls biodistribution as well as cell uptake. One of the most used methods is polyethylene glycol (PEG) modification, also known as PEGylation, which confers a hydrophilic corona that prevents opsonization and phagocytosis by the mononuclear phagocyte system ³¹. They form long circulation and enhanced targeting in target tissue. In addition to PEGylation, zwitterionic polymers, albumin, and

polysaccharides have been investigated to further enhance stealth. Targeting ligands may be covalently attached on surfaces to achieve active targeting. Surface charge and hydrophobicity are also significant in protein adsorption, aggregation, and immune recognition that also need to be precisely regulated during formulation.

3.4. Stimuli Responsive or Smart Delivery Systems

Stimuli-responsive NDDS are prepared to deliver drugs upon encountering certain internal or external stimuli. Such smart systems develop spatiotemporal control over drug release, improving the efficacy of drugs and lowering side effects ³². Internal stimuli are redox potential, temperature gradients in diseased tissues, enzyme activity, and pH. pH sensitive nanoparticles that break down in the acidic tumor or endosomal environment releasing the encapsulated drug are one example. Redox sensitive carriers break down by coming into contact with higher intracellular levels of glutathione for target release in target cells. Enzyme sensitive systems employ overexpressed enzymes like matrix metalloproteinases or phospholipases to initiate localized release of the drug. External stimuli are magnetic fields, ultrasound, light, and electrical signals. Magnetic nanoparticles can be directed to the target region by an external magnetic field and release drugs after thermal stimulation. Light-sensitive nanocarriers take advantage of photosensitive molecules that undergo conformational change upon exposure to light and make on demand precise drug delivery possible ³³.

3.5. Pharmacokinetic and Pharmacodynamic Considerations

A successful NDDS has to balance stability of formulation, drug release kinetics, and drug effect. Pharmacokinetic profile of a drug including absorption, distribution, metabolism, and excretion (ADME) controls drug exposure at the target site. Nanocarriers at the nanoscale can enhance absorption through lymphatic uptake, alter biodistribution by bypassing renal clearance, and decrease metabolic degradation³⁴.

Pharmacodynamic effects are dependent on drug concentration at the receptor site, receptor occupancy time and with biological targets. Controlled release NDDS maintain therapeutic concentration and minimize plasma concentration fluctuations, causing consistent pharmacological effect and decreased side effects. Physiologically based pharmacokinetic simulation and mathematical modeling are increasingly being utilized for drug release profile prediction and dosage regimen optimization for faster preclinical to the clinical stage transition of NDDS³⁵.

Table 2. Mechanistic Strategies and Functional Roles in Novel Drug Delivery Systems

Mechanism Strategy	Principle	Design Characteristics	Therapeutic Advantages
Controlled release	Diffusion, degradation, or erosion of matrix	Polymer composition, particle size, surface charge	Sustained plasma level, reduced dosing frequency
Passive targeting	Enhanced permeability and retention effect	Nanoscale dimension, long circulation time	Accumulation in tumor and inflamed tissue
Active targeting	Ligand receptor interaction	Surface conjugation with antibodies, folate, or peptides	Selective drug uptake, reduced systemic toxicity
Surface modification	Steric stabilization, stealth coating	PEG or polysaccharide layer, charge tuning	Prolonged circulation, immune evasion
Stimuli responsive systems	Triggered release by internal or external stimuli	pH, enzyme, temperature, redox, or magnetic activation	On demand site specific drug delivery
Pharmacokinetic optimization	Control of ADME parameters	Particle engineering, bio adhesion, targeting	Improved bioavailability and efficacy

In short, design and mechanistic strategies in novel drug delivery systems aim at accurate release control and targeting. By the inclusion of passive and active targeting with intelligent responsiveness and surface engineering, NDDS can have substantial impacts on therapeutic precision. Advances in the future will depend on predictive modeling, high-resolution imaging, and biomimetic design to further optimize these systems for personalized medicine.

4. NOVEL DRUG DELIVERY SYSTEMS FOR HERBAL AND PHYTOCHEMICAL DELIVERY

Phytochemicals isolated from medicinal herbs have exhibited a wide range of pharmacological activity such as antioxidant, anti-inflammatory, anticancer, and hepatoprotective activity. Their therapeutic efficacy is compromised by low aqueous solubility, degradation in biological matrices, poor permeability, and extensive metabolism. Such

factors lead to poor bioavailability and clinical efficacy³⁶. To overcome such limitations, nanotechnology-derived delivery systems have been found to enhance the solubility, stability, and absorbability of plant phytochemical constituents. Compatibility with new drug delivery systems such as liposomes, nanoemulsions, polymeric nanoparticles, and phytosomes facilitates the delivery of phytochemicals to the target tissue in an effective way and facilitates the controlled release of the drug³⁷.

4.1. Lipid-Based Carriers of Herbal Compounds

Lipid-based carriers are well-proven delivery systems for phytochemicals because they are bio-compatible and can encapsulate lipophilic molecules. Of these, liposomes and phytosomes are of special interest. Phytosomes are phospholipid-phytochemical complexes, which enhance the bioavailability of poorly soluble drugs. A good

example is silymarin phytosome preparation, which enhanced oral bioavailability of silybin very effectively and enhanced hepatoprotection in animal models³⁸. Shriram et al. proved that phospholipid phytosomes enhance the therapeutic activity of silymarin by enhancing membrane permeability and inhibiting oxidative degradation of the drug³⁹. Liposomal formulations were also utilized to improve the delivery of curcumin, quercetin, and resveratrol. Curcumin liposomes exhibited better bioavailability and antitumor activity than free curcumin by enhancing systemic stability and cell uptake⁴⁰. Liposomal formulations of quercetin also exhibited enhanced circulation time and enhanced antioxidant activity.

4.2. Polymeric Nanoparticles for Phytochemical Delivery

Polymeric nanoparticles have been identified as tunable and multifunctional platforms with the ability to encapsulate hydrophobic as well as hydrophilic natural products. They provide sustained release of the drug, enhancement in pharmacokinetic stability, and enhanced penetration into tissues⁴¹. Elmowafy et al. have documented that polymeric nanoparticles prepared from biodegradable polymers like polylactic acid and chitosan were effective in delivering natural bioactive agents with effective entrapment efficiency and enhanced cellular uptake⁴². Polymer-based encapsulation of curcumin or catechin, for instance, was shown to be more efficient in terms of bioavailability and antioxidant action with preclinical models. Polymeric nanocarriers are also useful for site-specific delivery of phytoconstituents. Chitosan nanoparticles are useful for mucosal delivery as the cationic character enables them to adsorb on negatively charged mucosal membranes. Such a property has been utilized for oral and nasal delivery of herbal preparations for improved absorption through the epithelial barriers.

4.3. Nanoemulsions and Other Lipid-Polymer Hybrids

Nanoemulsions are submicron oil and water emulsions stabilized by surfactants whose permeability and solubility improve poorly soluble phytochemicals⁴³. Curcumin nanoemulsions have been reported to exhibit superior improvement in oral bioavailability and antioxidant activity due to

improved dissolution and inhibition of gastrointestinal degradation. Sheng et al. indicated nanoemulsion formulation-based curcumin had higher plasma concentration and persistent pharmacologic action compared to raw curcumin powder. Hybrid lipid-polymer nanoparticles integrate the best of both systems and exhibit enhanced encapsulation stability and controlled drug release. These carriers induce multi-stage release processes, which are being rationally designed to suit the biological target. These types of systems are under investigation for multi-ingredient herbal preparations to deliver multiple phytoconstituents in simultaneous and synchronized manner.

4.4. Nanogels and Dendrimers for Herbal Applications

Nanogels and dendrimers are emerging as next-generation vehicles for the delivery of plant bioactive. Nanogels encapsulate hydrophilic phytochemicals in a cross-linked matrix with release triggered by swelling. Dendrimers on the other hand, are branched and therefore enable conjugation of the phytochemicals with surface functional groups, enhancing solubilization and cellular uptake^{44,45}. They offer new avenues of cancer and neuroprotection studies where phytochemicals such as curcumin, resveratrol, and catechins are enhanced in delivery and bioavailability through encapsulation using polymeric nanogels or dendrimer complexes. They are investigated for long-term administration since they are biocompatible and of trace toxicity.

4.5. Therapeutic Significance and Future Direction

NDDS may have revolutionized the process of drug preparations of herbal medicines via the improvement of pharmacokinetic properties, variability of dosing, and sustaining therapeutic levels. The use of nanotechnology in traditional phytotherapy represents a paradigm shift towards evidence-based phytotherapy for drugs⁴⁶. Current research focuses on optimizing carrier design by computer simulation and artificial intelligence to predict drug-carrier interactions. Future investment will be most likely in tailored delivery systems which optimize release profiles to match the patient-specific requirements without compromising safety and regulatory limits.

Table 3. Novel Drug Delivery Systems for Phytochemical Delivery

Type	Composition	Phytochemicals	Applications
Phytosomes	Phospholipid complex	Silymarin, Ginkgo biloba extract	Hepatoprotection, antioxidant therapy
Liposomal carriers	Phosphatidylcholine vesicles	Curcumin, Quercetin, Resveratrol	Anticancer, anti-inflammatory therapy
Polymeric nanoparticles	PLA, PCL, Chitosan	Curcumin, Catechin, Berberine	Antioxidant, antimicrobial delivery
Nanoemulsions	Oil-water emulsion with surfactants	Curcumin, Thymoquinone	Oral and parenteral delivery
Nanogels	Crosslinked polymer network	Curcumin, Resveratrol	Cancer and neuroprotective therapy
Dendrimers	Branched macromolecular polymer	Catechin, Gallic acid	Antioxidant and antimicrobial therapy

5. APPLICATIONS OF NOVEL DRUG DELIVERY SYSTEMS IN MODERN THERAPEUTICS

Next-generation drug delivery systems have a pivotal position in modern therapeutic strategies by enhancing drug delivery, restricting off target toxicity, and facilitating new therapeutics. Major clinical and preclinical applications in this category include cancer therapy, neurological disorders, infectious disease management, gene and peptide delivery, and transdermal and mucosal delivery. Focus is given to mechanistic rationale, representative technologies, translational concerns, and landmark examples in the literature.

5.1. Cancer therapy

Cancer remains one of the first target areas for emerging delivery systems because most cytotoxic agents have narrow therapeutic windows. Nanocarriers can be used to modulate biodistribution and pharmacokinetics to improve tumor exposure while reducing systemic toxicity. Methods include encapsulation for improving solubility and stability, size dependent passive

uptake in tumor tissue by the enhanced permeability and retention effect, and ligand mediated active targeting of receptors overexpressed on cancer cells⁴⁷. Stimuli responsive carriers which release payloads upon acidic pH, redox potential, or presence of particular enzymes make intratumoral specificity more feasible and enable on demand drug release in the tumor microenvironment⁴⁸. Anthracycline and other payload liposomal products document decreased cardiotoxicity and increased tolerability compared to free drug. Polymer-based nanoparticles and polymer lipid hybrids are employed for the delivery of small molecule and nucleic acid therapeutics and are under investigation as combination with immunotherapy for tumor immune microenvironment modulation⁴⁹. There are significant translational difficulties in oncology such as reproducible production, batch-to-batch comparability, and stable biomarkers for identifying which tumors will effectively take up nanoparticles. The involved interplay among particle attributes and tumor pathophysiology demands rational design under the guidance of preclinical pharmacokinetics and imaging assessments⁵⁰.




Fig 4: Applications of Novel Drug Delivery Systems

5.2. Neurological illnesses

The delivery of therapeutics into the central nervous system is hindered by the blood brain barrier, a strong physiological barrier that inhibits passive drug movement. New carriers offer several strategies for breaching this hurdle. Strategies include reversible disruption of barrier tight junctions, receptor-mediated transcytosis using ligands like transferrin or insulin-like peptides and utilization of carrier mediated transporters. Lipid nanocarriers and polymeric nanocarriers may be surface engineered to improve brain delivery and maintain payloads from premature clearance. Exosomes and other biomimetic vesicles are very promising as natively brain tolerant carriers because they are of endogenous origin and possess natural tropism^{50, 51}. For brain cancer and neurodegenerative disease, nanoparticle formulations can shield labile small molecules and nucleic acids from enzymatic breakdown and deliver therapeutic levels to the targeted regions in the brain. Safety evaluation for brain targeting needs to consider very carefully neuroinflammation, long-term survival, and interference in usual barrier function. Physiologically based pharmacokinetic modeling and intravital imaging are strong tools to maximize design and dosing regimens⁵².

5.3. Infectious disease and antimicrobial therapy

Delivery systems are designed to address antimicrobial resistance and optimize the therapeutic ratio of current agents. Nanoparticles could be used to increase the local concentration of the antibiotic at the site of infection, provide sustained release that decreases dosing frequency, and provide combination therapies synergistically active against the pathogen⁵³. Metal nanoparticle-based nanoparticles like silver and zinc oxide have intrinsic antimicrobial activity and are developed into device and topical related coatings. Liposomal and polymer-based carriers are employed for intracellular space and biofilm occupied by pathogens penetration. Vaccine performance is enhanced by delivery systems as well through regulation of antigen presentation along with adjuvant co-delivery, thus enhancing immunity and restricting reactogenicity. Translation encompasses evidence of safety to host tissues, evaluation of environmental impact of nanoparticle excretion, and

prevention strategies for promoting resistance to nanoparticle-based modalities⁵⁴.

5.4. Gene and peptide delivery

Nucleic acid therapeutics and therapeutic peptides need protection of carriers due to fragility in biological fluids, lack of permeability across membranes, and rapid renal elimination upon systemic delivery. Non-viral carriers like lipid nanoparticles and polymeric carriers are less immunogenic and safer than viral carriers but find applications in situations where absolute high transfection efficiency is a prerequisite. Lipid nanoparticle technology facilitated the production of mRNA-based vaccines and medicines in the short term through the targeting of mRNA and endosomal escape, thus allowing cytosolic translation. Peptide drugs may be aided by nanogel encapsulation or surface adsorption onto nanoparticles to prolong circulation half-life and allow controlled release at target tissues. Intracellular delivery requires endosomal escape and lysosomal resistance functionalities to facilitate effective delivery. Modular structure, e.g., pH responsive or redox responsive chemistries, has been used to allow cytosolic delivery and gene expression^{53,54}.

5.5. Transdermal and mucosal delivery

Mucosal and transdermal delivery provide non-invasive administration and are linked with the benefit of prevention of first pass hepatic metabolism. Permeation enhancement technologies for epithelial barriers include lipid-based vesicles for optimum fluidity, nanoscale carrier sized vehicles employing follicular pathways, and micro formulation aided strategies like iontophoresis and microneedles. Ethanol filled vesicles and transfersome type formulations enhance the skin permeability to small molecule and macromolecular therapeutics. Buccal and nasal nanocarriers enable rapid systemic absorption or direct entry into the central nervous system via olfactory routes. Controlled release implants and mucoadhesive nanoparticles are designed for chronic local treatment and improved patient compliance^{54,55}. Local tolerability, barrier integrity, reproducibility of absorption in different patient populations, and device regulatory acceptability for combination products are the principal concerns.

Table 4. NDDS Applications and Mechanistic Rationale

Therapeutic Area	Carrier Types	Mechanistic Rationale
Cancer therapy	Liposomes, polymeric nanoparticles, polymer lipid hybrids, stimuli responsive carriers	Improve solubility and stability, passive and active targeting, triggered release in tumor microenvironment
Neurological disorders	Functionalized nanoparticles, exosomes, receptor targeted vesicles	Receptor mediated transcytosis, transporter exploitation, protection of labile cargo
Infectious disease	Liposomal antibiotics, metal nanoparticles, nanoemulsions, vaccine nanoparticles	Enhanced local concentration, biofilm penetration, antigen presentation control
Gene and peptide delivery	Lipid nanoparticles, polymeric vectors, nanogels, viral vectors	Protection from nucleases, facilitation of cellular uptake and endosomal escape
Transdermal and mucosal delivery	Ethosome like vesicles, transfersome like vesicles, mucoadhesive nanoparticles, microneedles	Enhanced epithelial permeation, avoidance of first pass metabolism, sustained local release

6. CLINICAL TRANSLATION AND REGULATORY PERSPECTIVES OF NDDS

Clinical translation of novel drug delivery systems is a highly significant innovation-practice interface in therapeutics. The systems potentially have the ability to provide greater safety, efficacy, and patient compliance but are limited by complex scientific, regulatory, and economic barriers from entering the marketplace. Translation is effective when a multidisciplinary strategy combines formulation science, toxicology, modeling, and regulatory science into one integrated model of development.

6.1. Quality by Design and Analytical Characterization

The basis of clinical translation starts from characterization of sound and definition of quality attributes. In vitro properties like particle size, zeta potential, morphology, encapsulation efficiency, and release kinetics define NDDS's in vivo performance⁵⁶. Advanced instrumentation such as dynamic light scattering, atomic force microscopy, nanoparticle tracking analysis, and calorimetric profiling can accurately measure these properties. Establishing critical quality attributes and their influence on biological performance is key to reproducibility and safety. Quality by Design philosophy enables the identification of key process and formulation parameters, which are to be controlled in order to provide batch consistency and product reliability when transferred to a large scale.

6.2. Reproducibility in Manufacturing and Scale Transition

Scaling up nanocarriers from bench to factory is technically demanding. Kinetics of mixing, addition of energy, and penetration of the solvent can be different, causing modifications in size and morphology and drug loading and stability⁵⁷. Continuous processing and microfluidic methods are becoming increasingly desired as better alternatives to conventional batch processes, enabling self-assembly kinetics controlled tuning and monitoring in real time. Reproducible and scalable processes are imperative for qualification by the authorities and cost-effective commercialization.

6.3. Preclinical Toxicological Profiling and Safety

Evaluation of safety is also a prime driver of clinical potency. Nanocarriers can engage with biological systems in unforeseen manners because of their submicroscopic size, high surface area, and distinct reactivity⁵⁸. Toxicology models that are nonnanoparticle-based cannot always replicate these effects, and therefore nanoparticle-specific biodistribution, accumulation, immunogenicity, and genotoxicity determination must be performed. Corona formation on proteins has the ability to modify immune and clearance mechanism identification, carrier destiny, and toxicity profile. Early inclusion of sophisticated in vitro tests and in silico predictions can minimize reliance on animal models with more predictive ability for human response.

6.4. Immunological and Biological Interactions

The immune system performs a bimodal function in NDDS performance. While some nanocarriers are constructed to engage immune cells in immunotherapy or vaccines, unintended stimulation can cause hypersensitivity responses or premature clearance⁵⁹. Activation of complement, cytokine induction, and antibody production must be included in preclinical studies. Stealth polymers or biomimetic coatings to surface modification will avoid immune detection and extend the time of circulation. Knowledge of the immunological profile of each formulation is essential in attempting to engineer safer and more consistent delivery systems.

6.5. Pharmacokinetic Modeling and Predictive Translation

A basic understanding of pharmacokinetic and pharmacodynamic behavior is essential to rational selection of dosage. Clearance and organ distribution mechanisms of nanoparticles can be understood using physiologically based pharmacokinetic (PBPK) modeling⁶⁰. Integrating anatomical and physiological parameters with physicochemical characteristics, PBPK models enable human dose extrapolation and early-phase clinical trial design. Coupling the model with noninvasive imaging allows visualization of in vivo distribution, speeding up the translation process.

6.6. Regulatory Environment and Global Frameworks

Regulatory monitoring of nanomedicines persists. Agencies like the European Medicines Agency and the United States Food and Drug Administration have released reflection documents and technical guidances on nanotechnology-facilitated products⁶¹. These involve comprehensive characterization, validated analytical methods, and risk-based methodologies in assessment. Early consultation with regulators at the initial stages of product development can expedite approval and demystify data expectations. The creation of globally harmonized standards will be necessary to ensure world-wide acceptability of NDDS.

6.7. Environmental and Post-Market Safety

Besides clinical safety, environmental impact is also coming to be considered as a new area. Released

during manufacture or excreted through patients, nanoparticles can have the possibility of migrating into the environment and influencing microbial or aquatic life⁶². Environmental risk assessment and life cycle assessment must be included in regulatory reports. Long-term monitoring after approval of the product is also required to detect rare or delayed adverse effects and ensure sustainable use of nanotechnology drugs.

6.8. Optimization of Clinical Trials and Stratification of Patients

Clinical testing of NDDS requires creative trial designs that also mirror the complexity of the systems. Imaging biomarkers and companion diagnostics assist in the confirmation of drug distribution and target engagement⁶³. Patient stratification by genetic, metabolic, or receptor-expression profiles enhances the probability of showing efficacy in specific subpopulations. Adaptive and model-informed clinical trial designs can also expedite decision-making without losing scientific integrity.

6.9. Economic Viability and Ethical Management

The economic sustainability of NDDS depends upon manufacturing cost, economies of scale, and competitive marketplace. Expensive production usually limits Third World access, where low-cost formulating techniques and technology transfer models are called for⁶⁴. Institutional structures for collaboration between academia, industry, and regulatory institutions can contribute towards striking a balance between innovation and social responsibility.

6.10. Future Directions

The future of NDDS translation is to integrate multidisciplinary know-how with an unbroken continuum of development. Computationally guided prediction modeling, artificial intelligence-based design, and bioimaging will be increasingly engaged in formulation optimization. Greater transparency of data in communication and use of standardized test protocols will enhance regulatory confidence. Quality by Design and risk-based approaches from the beginning of research will enhance clinical acceptability and market readiness. Finally, NDDS success will hinge on reconciling safety, sustainability, and accessibility with scientific innovation.

7. CONCLUSION

The innovation of new drug delivery systems has revolutionized the pharmaceutical landscape by providing more intelligent, safer, and better treatments. They have transcended conventional dose forms by offering controlled and targeted drug delivery by employing nanotechnology, polymer science, and molecular targeting. Their ability to improve the pharmacokinetic profile, minimize adverse effects, and promote patient compliance has made NDDS the foundation of modern-day pharmaceuticals. Despite significant advances, certain limitations still exist to limit their overall translation into the universal. Complex synthesis mechanisms, issues related to instability, and high production costs are the major limitations for broader application. Long-term safety, immunologic tolerance, and environmental sustainability are also relevant issues. Lack of harmonized regulation frameworks among international agencies carries a factor of complexity as well, which results in delaying product clearance and market entry. Removal of these impediments is best achieved through concerted action between academia, industry, and regulatory agencies to develop standardized approaches to characterization, testing, and risk assessment. The destiny of NDDS will be characterized by convergence of sophisticated sciences. Computational simulations and artificial intelligence will be key roles in prediction of

formulation performance, drug loading optimization, and therapy customization to patient individual biological profiles. Biomimetic and stimulus responsive system design will also lead the way in precision medicine through adaptive response to physiological states. Concurrently, application of principles of green chemistry will facilitate realization of sustainable development with reduced environmental footprint. Over the next two decades, NDDS will transcend the conventional space of drugs and find novel territories in areas of gene therapy, regenerative medicine, nutraceuticals, and vaccine technology. The aim is to translate laboratory innovation at the bedside as therapeutics that are relevant to clinics, low in cost, and accessible to the world. This will be facilitated by an infinite cycle of scientific innovation, sagacious regulation, and patient-focused design. Through this approach of interdisciplinarity, drug delivery systems in the future will keep redesigning the shape of medicine and setting higher standards for healthcare in the world.

Acknowledgments

The authors gratefully acknowledge the support provided by Mata Gujri University for facilitating this work. This study was partially supported by the university through academic and institutional research assistance.

REFERENCES

1. Langer R. Drug delivery and targeting. *Nature*. 1998;392(6679 Suppl):5-10.
2. Allen TM, Cullis PR. Drug delivery systems: entering the mainstream. *Science*. 2004;303(5665):1818-22.
3. Sharma A, Sharma US. Liposomes in drug delivery: progress and limitations. *Int J Pharm*. 1997;154(2):123-40.
4. Park K. Controlled drug delivery systems: past forward and future back. *J Control Release*. 2014;190:3-8.
5. Petros RA, DeSimone JM. Strategies in the design of nanoparticles for therapeutic applications. *Nat Rev Drug Discov*. 2010;9(8):615-27.
6. Torchilin VP. Multifunctional nanocarriers. *Adv Drug Deliv Rev*. 2012;64(13):302-15.
7. Mitragotri S, Burke PA, Langer R. Overcoming the challenges in administering biopharmaceuticals: formulation and delivery strategies. *Nat Rev Drug Discov*. 2014;13(9):655-72.
8. Peer D, Karp JM, Hong S, Farokhzad OC, Margalit R, Langer R. Nanocarriers as an emerging platform for cancer therapy. *Nat Nanotechnol*. 2007;2(12):751-60.
9. Jain KK. Advances in the field of nano oncology. *Expert Rev Mol Diagn*. 2008;8(3):307-20.
10. Shi J, Kantoff PW, Wooster R, Farokhzad OC. Cancer nanomedicine: progress, challenges and opportunities. *Nat Rev Cancer*. 2017;17(1):20-37.
11. Brigger I, Dubernet C, Couvreur P. Nanoparticles in cancer therapy and diagnosis. *Adv Drug Deliv Rev*. 2012;64(1):24-36.
12. Zhao Y, Fay F, Hak S, Perez-Aguilar JM, Sanchez-Gaytan BL, Goode B, et al. Augmenting drug-carrier compatibility improves tumour nanotherapy efficacy. *Nat Commun*. 2016;7:11221.

13. Li J, Mooney DJ. Designing hydrogels for controlled drug delivery. *Nat Rev Mater.* 2016;1(12):16071.
14. Duncan R, Gaspar R. Nanomedicine(s) under the microscope. *Mol Pharm.* 2011;8(6):2101-41.
15. Sanna V, Sechi M. Nanoparticle therapeutics for the delivery of natural bioactives. *J Control Release.* 2020;325:301-17.
16. Mehnert W, Mäder K. Solid lipid nanoparticles: production, characterization and applications. *Adv Drug Deliv Rev.* 2012;64(1):83-101.
17. Akbarzadeh A, Rezaei-Sadabady R, Davaran S, Joo SW, Zarghami N, Hanifepour Y, et al. Liposome: classification, preparation, and applications. *Nanoscale Res Lett.* 2013;8(1):102.
18. Barenholz Y. Doxil—the first FDA approved nano-drug: lessons learned. *J Control Release.* 2012;160(2):117-34.
19. Moghassemi S, Hadjizadeh A. Nano-niosomes as nanoscale drug delivery systems: an illustrated review. *J Control Release.* 2014;185:22-36.
20. Müller RH, Radtke M, Wissing SA. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) in cosmetic and pharmaceutical applications. *Adv Drug Deliv Rev.* 2002;54(Suppl 1):S131-55.
21. Cevc G, Blume G. Lipid vesicles penetrate into intact skin owing to the transdermal osmotic gradients and hydration forces. *Biochim Biophys Acta.* 1992;1104(1):226-32.
22. Touthou E, Dayan N, Bergelson L, Godin B, Eliaz M. Ethosomes—novel vesicular carriers for enhanced delivery: characterization and skin penetration properties. *J Control Release.* 2000;65(3):403-18.
23. Kumari A, Yadav SK, Yadav SC. Biodegradable polymeric nanoparticles based drug delivery systems. *Colloids Surf B Biointerfaces.* 2010;75(1):1-18.
24. Tomalia DA, Baker H, Dewald J, Hall M, Kallos G, Martin S, et al. Dendritic macromolecules: synthesis of starburst dendrimers. *Macromolecules.* 1986;19(9):2466-68.
25. Date AA, Hanes J, Ensign LM. Nanoparticles for oral delivery: design, evaluation and state-of-the-art. *J Control Release.* 2016;240:504-26.
26. Siepmann J, Siepmann F. Modeling of diffusion controlled drug delivery. *J Control Release.* 2012;161(2):351-62.
27. Dash S, Murthy PN, Nath L, Chowdhury P. Kinetic modeling on drug release from controlled drug delivery systems. *Acta Pol Pharm.* 2010;67(3):217-23.
28. Fang J, Nakamura H, Maeda H. The EPR effect: unique features of tumor blood vessels for drug delivery, factors involved, and limitations. *Adv Drug Deliv Rev.* 2011;63(3):136-51.
29. Jain RK, Stylianopoulos T. Delivering nanomedicine to solid tumors. *Nat Rev Clin Oncol.* 2010;7(11):653-64.
30. Byrne JD, Betancourt T, Brannon-Peppas L. Active targeting schemes for nanoparticle systems in cancer therapeutics. *Adv Drug Deliv Rev.* 2008;60(15):1615-26.
31. Knop K, Hoogenboom R, Fischer D, Schubert US. Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. *Angew Chem Int Ed Engl.* 2010;49(36):6288-6308.
32. Mura S, Nicolas J, Couvreur P. Stimuli responsive nanocarriers for drug delivery. *Nat Mater.* 2013;12(11):991-1003.
33. Qiu Y, Park K. Environment sensitive hydrogels for drug delivery. *Adv Drug Deliv Rev.* 2012;64(Suppl):49-60.
34. Blanco E, Shen H, Ferrari M. Principles of nanoparticle design for overcoming biological barriers to drug delivery. *Nat Biotechnol.* 2015;33(9):941-51.
35. Li M, Al-Jamal KT, Kostarelos K, Reineke J. Physiologically based pharmacokinetic modeling of nanoparticles. *ACS Nano.* 2010;4(11):6303-17.
36. Rudrapal M, Mishra AK, Rani L, Khomendra K. Nanodelivery of dietary polyphenols for therapeutic applications. *Molecules.* 2022;27(24):8706.
37. Sanna V, Sechi M. Nanoparticle therapeutics for the delivery of natural bioactive compounds. *Expert Opin Drug Deliv.* 2020;17(7):979-95.
38. Loguercio C, Festi D. Silybin and the liver: from basic research to clinical practice. *World J Gastroenterol.* 2011;17(18):2288-301.
39. Shriram RG, Moin A, Alotaibi HF, Al Saqr A, Charyulu RN. Phytosomes as a plausible nano delivery system for enhanced oral bioavailability and improved hepatoprotective activity of silymarin. *Pharmaceuticals (Basel).* 2022;15(7):790.
40. Bulboacă AE, Porfire AS, Bolboacă SD, Dogaru G, Lupșe M, Răjnoveanu RM, et al. Comparative effect of curcumin versus liposomal curcumin on oxidative stress and inflammation in experimental ischemia. *Molecules.* 2019;24(13):2426.
41. Barani M, Sangiovanni E, Gariani G, Zare EN, Yazdi MH, Sitia L, et al. Phytosomes as innovative delivery systems for polyphenols. *Nanomaterials.* 2021;11(4):995.
42. Elmowafy M, Shalaby K, Elkomy MH, Alsaïdan OA, Gomaa HAM, Abdelgawad MA, Mostafa EM. Polymeric nanoparticles for delivery of natural bioactive agents: recent advances and challenges. *Polymers (Basel).* 2023;15(5):1123.

43. Gonçalves RFS, Silva CE, Afonso J, de Matos AM, Cerqueira MA, Vicente AA. Nanoemulsions for enhancement of curcumin bioavailability: formulation, digestion and uptake. *Nanomaterials*. 2021;11(3):815.
44. Sarkar B, Roy SD, Shil D. Nanogels as next-generation drug delivery systems: design, advances, and biomedical applications. *J Biol Methods*. 2025;13(1):e99010090.
45. Sarkar S, Sarkar B. Carbopol 940-based metronidazole nanogels: formulation, physicochemical characterization, in vitro drug release, and antimicrobial evaluation. *Front Soft Matter*. 2026;6:1912568.
46. Patel A, Patel J, Singh D. Integration of nanotechnology in herbal medicine: current status and future perspectives. *J Pharm Investig*. 2020;50(4):281-94.
47. Saraiva C, Praça C, Ferreira R, Santos T, Ferreira L, Bernardino L. Nanoparticle-mediated brain drug delivery: overcoming the blood–brain barrier to treat neurodegenerative diseases. *J Control Release*. 2016;235:34-47.
48. Pelgrift RY, Friedman AJ. Nanotechnology as a therapeutic tool to combat microbial resistance. *Adv Drug Deliv Rev*. 2013;65(13-14):1803-15.
49. Yin H, Kanasty RL, Eltoukhy AA, Vegas AJ, Dorkin JR, Anderson DG. Non-viral vectors for gene-based therapy. *Nat Rev Genet*. 2014;15(8):541-55.
50. Prausnitz MR, Langer R. Transdermal drug delivery. *Nat Biotechnol*. 2008;26(11):1261-8.
51. Pardi N, Hogan MJ, Porter FW, Weissman D. mRNA vaccines—a new era in vaccinology. *Nat Rev Drug Discov*. 2018;17(4):261-79.
52. Zhang L, Gu FX, Chan JM, Wang AZ, Langer RS, Farokhzad OC. Nanoparticles in medicine: therapeutic applications and developments. *Clin Pharmacol Ther*. 2008;83(5):761-9.
53. Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Préat V. PLGA-based nanoparticles: an overview of biomedical applications. *J Control Release*. 2012;161(2):505-22.
54. Wang AZ, Langer R, Farokhzad OC. Nanoparticle delivery of cancer drugs. *Annu Rev Med*. 2012;63:185-98.
55. Ventola CL. Progress in nanomedicine: approved and investigational nanodrugs. *P T*. 2017;42(12):742-55.
56. Etheridge ML, Campbell SA, Erdman AG, Haynes CL, Wolf SM, McCullough J. The big picture on nanomedicine: the state of investigational and approved nanomedicine products. *Nanomedicine*. 2013;9(1):1-14.
57. De Jong WH, Borm PJ. Drug delivery and nanoparticles: applications and hazards. *Int J Nanomedicine*. 2008;3(2):133-49.
58. Nel A, Xia T, Madler L, Li N. Toxic potential of materials at the nanolevel. *Science*. 2006;311(5761):622-7.
59. Fadeel B, Garcia-Bennett AE. Better safe than sorry: understanding the toxicological properties of inorganic nanoparticles. *Adv Drug Deliv Rev*. 2010;62(3):362-74.
60. European Medicines Agency. Reflection paper on nanotechnology-based medicinal products for human use. EMA; 2006.
61. Gottschalk F, Nowack B. The release of engineered nanomaterials to the environment. *J Environ Monit*. 2011;13(5):1145-55.
62. Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. *Science*. 2018;359(6382):1350-5.
63. Alexis F, Pridgen E, Molnar LK, Farokhzad OC. Factors affecting the clearance and biodistribution of polymeric nanoparticles. *Mol Pharm*. 2008;5(4):505-15.
64. Dobrovolskaia MA, McNeil SE. Immunological properties of engineered nanomaterials. *Nat Nanotechnol*. 2007;2(8):469-78.

CONFLICT OF INTEREST REPORTED: NIL; SOURCE OF FUNDING: NONE REPORTED